Khaleej Times

Curbs take toll on children

-

damascus — In the cancer ward at Damascus Children’s Hospital, doctors are struggling with a critical shortage of specialist drugs to treat their young patients — and it’s not just due to the general chaos of the Syrian civil war.

Local and World Health Organisati­on (WHO) officials also blame Western sanctions for severely restrictin­g pharmaceut­ical imports, even though medical supplies are largely exempt from measures imposed by the United States and European Union.

Six years of conflict have brought the Syrian health service, once one of the best in the Middle East, close to collapse. Fewer than half of the country’s hospitals are fully functionin­g and numbers of doctors have dived.

The result is tumbling life expectancy — even after accounting for the hundreds of thousands directly killed in the fighting — and soaring deaths in pregnancy and childbirth.

On top of this, cuts in health spending by the government that is fighting a hugely expensive war, a drastic fall in the Syrian currency and indirect effects of the sanctions are all deepening the misery of patients who need foreign-made drugs.

For families with sick children, the situation is dire.

At the children’s hospital in government-held Damascus, the waiting room outside the cancer ward was crowded with relatives, many of whom had brought clothes, mattresses and blankets in case they had to spend long periods far from their homes outside the city.

One of them was Naim Der Moussa, 55, who has been living in Damascus for a year to secure regular treatment for his 10-year-old daughter Waad. They left his wife and six other children behind in the city of Deir AlZor, where government forces are besieged by Daesh.

“My daughter was first diagnosed with kidney cancer and treated,” he said. “Now cancer has been found also in her lungs.”

Before the conflict, Syria produced 90 per cent of the medicines it needed but anti-cancer drugs were

The proportion of patients who need assistance has risen from about 30 per cent to nearly 80 per cent since the war began rima salem Executive manager, Basma

among those where it traditiona­lly relied on imports.

Elizabeth Hoff, the WHO representa­tive in Syria, said medicine imports have been hit by significan­t cuts in the government’s health budget since the war began in 2011 plus a 90 per cent drop in the value of the Syrian pound, which has made some pharmaceut­icals prohibitiv­ely expensive.

However, a lack of cash is not the only reason why supplies of cancer drugs are falling far short of increasing demand.

“The impact of economic sanctions imposed on Syria heavily affected the procuremen­t of some specific medicine including anti-cancer medicines,” said Hoff. The sanctions were preventing many internatio­nal pharmaceut­ical companies from dealing with the Syrian authoritie­s as well as hindering foreign banks in handling payments for imported drugs, she added.

The United States and EU have imposed a range of measures targeted both at the government and some of the many armed groups operating in the country.

Washington has banned the export or sale of goods and services to Syria from the United States or by US citizens. The EU has imposed travel bans, asset freezes and an arms embargo, with sanctions also targeting financial ties with Syrian institutio­ns, buying oil and gas from the country or investing in its energy industry. President Bashar Al Assad has partly blamed the sanctions for turning many Syrians into refugees, often heading to Europe.

Both the US and EU regimes include exemptions for medicines and other humanitari­an supplies. However, by clamping down on financial transactio­ns and barring much business with the Syrian government, the sanctions are indirectly affecting trade in pharmaceut­icals.

Many drugs companies have erred on the side of caution, avoiding any business with Syria for fear of inadverten­tly falling foul of the sanctions. The US State Department said the Treasury had authorised services in support of humanitari­an activities in Syria, adding that there were legal ways to bring medicine into the country.

The EU also rejected criticism of its sanctions. “Such measures are not aimed at the civilian population,” an EU spokeswoma­n said. “EU sanctions do not apply to key sectors of the Syrian economy such as food and medicine.”

She acknowledg­ed firms had increasing­ly pulled out of business with Syria but said this was also due to other reasons, including “security, reputation, commercial motivation, anti-money laundering measures” and the presence of jihadist groups.

The WHO brings essential medicines and medical supplies into Syria, procuring generic drugs from approved sources in Europe, North Africa and Asia. Branded US products cannot be imported due to the sanctions situation, Hoff said.

With funds from Kuwait, the WHO has delivered life-saving medicine including to more than 16,000 cancer patients, of whom thousands are children with leukaemia.

But this does not meet demand. Besides cancer medication, there are critical shortages of insulin, anaestheti­cs, specific antibiotic­s needed for intensive care, serums, intravenou­s fluids and other blood products and vaccines, Hoff said. —

 ?? Reuters ?? Syrian boy Fahd plays with a mobile phone next to his mother as he receives treatment for cancer at Damascus Children’s Hospital.—
Reuters Syrian boy Fahd plays with a mobile phone next to his mother as he receives treatment for cancer at Damascus Children’s Hospital.—

Newspapers in English

Newspapers from United Arab Emirates